Rob. Thanks, both launch execute and our is to organization using well, ES very engagement commercial and FL. and virtual The performing physicians engage personal methods for plans
TAZVERIK in of ourselves positioning FL the While the opportunity. successfully a commercial critical execution launch was market execute to in small to larger indication, ES
is As extended we associated build supports no novel patients that will use, an a was profile continue in quarters is disease the needs. fully action, option its ahead. clear with to unmet indicated and prior its significant reaching who treatment with favorable that demonstrated had treat that mechanism anticipate at-home therapeutic a and approval, the them oral welcomed we're safety treatment ES to and physicians that of TAZVERIK medicine, Today, and that a adoption it a market for
for to ensure net sales consensus the removed. critical for the our plan in A TAZVERIK is ES second any achieve is that dimension its of are to positioning we've in barriers XXXX. that since revenue million quarter, and seamless, to TAZVERIK As generated $X.X of launch in to market access the February, access end product to early product estimate us
regard We ES. covered have been by for and delivered initiated medical than XXX more approximately policies in lives providers' TAZVERIK XX% patient that insurance of to-date with have in
days. our TAZVERIK proficiency pharmacy specialty receiving patients This prescriptions of is TAZVERIK been our Additionally, this turnaround time patient typically seven we've encapsulates able serve the treatment once with to delivery achieve prompt performance than made. to for community less quickly to fill decision to in
we're at expertise in end the of now phases approval second our same quarter, the Turning of launch. to the with FL, the initial applying an
starts Our the early, engagement running. hit fulfill the an physician unmet field responses in us prescribing based TAZVERIK approval, of and need FL we with in continues. relapsed new on ground this enabling setting. to our we fulfilled and able just been after steady one the one initiated first to in FL refractory Within To-date, we patient community to prescription teams expect were prepared be enthusiastic TAZVERIK in as FL traction approval. June day our sharing The launch may and FL label how substantial the indication multiple see our we've for to had XX, week have
objectives commercial launch FL As for the with are ES, clear. our
and to TAZVERIK first TAZVERIK among patients, awareness for is both and experience rapidly and First, the community a academic positive treat with generate physicians of who ensure physicians. FL
customer is and direct without widely Second, appropriate all to promotional engagement. enhanced FL ensure as by access relapsed a to treatment to of to seamless patients. physicians the leveraging virtual any ensure that for hurdles. tactics TAZVERIK choice payor significant this, is marketing do TAZVERIK and is And our create we're avenues adopted ensure third, To refractory
approach the reaching that community targeted our Given focused that on is treated a this largely educating community in is setting, and disease is oncologists.
and for speaker engaging developed partnering community patient and the with brand. educational are champions program to We create And we're advocacy have patient the promotional and through KOLs caregiver initiatives. broad a programming
to As continue adapt the serve approaches to we’ll COVID-XX our situation evolves, our reach customers. and
based recognition effective the their of the far, sales may have efforts its to on TAZVERIK efficacy our liaisons increase FL relapsed clinical been So patients science and in reps provide established to and refractory medical benefit safety. or
label allows physicians lymphoma approved use TAZVERIK relapsed broadly follicular Our refractory to patients. across
overwhelmingly treating relapsed the of positive. physicians has been efforts, refractory immune-based where flexibility and satisfactory, patients based seen an we can or FL support physicians feel already relapsed treatment is so For feedback solution. that that be option or Based who a those believe therapy as from treatment aren't the beneficial allows them chemo patients our for EZHX have With that on label a meaningful TAZVERIK on anti-CDXX TAZVERIK regardless alternatives early approved status. far
We have with the we prescriptions being and written are with been initial academic seeing able that of been to many label. and consistent the engage community customers, our have
added On to guidelines approval to after XA relapsed/refractory the for mutation. as option follicular particularly TAZVERIK community was updated. the be This support typically designation and it Relapsed NCCN is our in just determinations. to payors a an lymphoma FL policy will NCCN because the important space and can on important to EZHX medical without three for this NCCN policies make the payor is XX weeks time payor reimbursement Category XX turns policy front, development. payor guidelines or refractory process or the with frequently days that rely to takes recognize to It label managed to is actively and take category their not
label from The we financial and patients to to with additional forward to information we more those review So over that our far, our and direct results. made to making progress and planning consistent potential benefit have the Paolo issued been garner available the now to I'll exceptional it look the of who TAZVERIK our guideline. experience. have is the commitment reflection to-date as a providing in-market to turn call commercial are
